Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-11 | 2024-09 | -0.05 | N/A | N/A | N/A |
2024-08-12 | 2024-06 | -0.05 | -0.05 | N/A | N/A |
2024-05-13 | 2024-03 | -0.07 | -0.05 | 0.02 | 28.57% |
2024-04-01 | 2023-12 | -0.05 | -0.06 | -0.01 | -20.00% |
2023-11-13 | 2023-09 | 0 | -0.05 | N/A | N/A |
2023-08-14 | 2023-06 | 0 | -0.06 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-07 | Cantor Fitzgerald | Upgrade | Overweight | |
2020-09-16 | Ascendiant Capital | Upgrade | Buy | |
2019-12-17 | Maxim Group | Upgrade | Hold | Buy |
2018-01-25 | Maxim Group | Upgrade | Buy | |
2013-10-06 | Sidoti & Co. | Downgrade | Buy | Neutral |
2013-04-14 | Sidoti & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2016-03-08 | CHEN SHU-CHIH | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
2013-05-14 | CROSS ALEXANDER DENNIS | Director | 0.00 | Purchase |
2024-04-09 | FINN JONATHAN F. | Director | 25.00K | Purchase |
2017-11-14 | GUSE KYLE | General Counsel | 10.00K | Purchase |
2016-03-08 | QUAY STEVEN C | Chief Executive Officer | 0.00 | Purchase |
2017-04-16 | REMMEL H LAWRENCE | Director | 3.13K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 5.68M | 7.15M | 4.51% |
2023-06-29 | Blackrock Inc. | 2.90M | 3.65M | 2.30% |
2023-06-29 | Laurion Capital Management, LP | 2.23M | 2.80M | 1.77% |
2023-06-29 | Geode Capital Management, LLC | 1.11M | 1.40M | 0.88% |
2023-06-29 | Renaissance Technologies, LLC | 1.07M | 1.35M | 0.85% |
2023-06-29 | State Street Corporation | 436.27K | 549.70K | 0.35% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.78M | 4.76M | 3.00% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.66M | 2.10M | 1.32% |
2023-05-30 | Fidelity Extended Market Index Fund | 659.95K | 613.75K | 0.52% |
2023-05-30 | BlackRock Advantage Small Cap Core Fund | 340.50K | 316.67K | 0.27% |
2023-05-30 | Fidelity Total Market Index Fund | 182.91K | 170.11K | 0.15% |
2023-05-30 | Fidelity Series Total Market Index Fund | 142.17K | 132.22K | 0.11% |
Split | Date |
---|---|
1 : 12 | 2018-04-20 |
1 : 15 | 2016-08-26 |
-
Nice position Chris
-
Because some of us actually swing our shares to make actual money, Jerry. You keep clutching those 500 shares and praying for $6 though.
-
It’s why they are a buyout candidate. They have promising products, but management lacks the ability to properly develop it and take it to market. PR is non-existent, they don’t understand how to properly utilize dropping news at the appropriate times. They could have raised all the capital they needed had they done it correctly, instead they try to force a vote for dilution through and got a resounding NO from shareholders. Why? Because you gave them nothing to sway their opinion. Still no update after it being promised months ago.
Hopefully big pharma with solid development
team buys this out. Ton of potential, just needs guidance. 26k shares, Holding 10k shares back in case of news, swinging the other 16k. Could blow up today or could be 6 months down the road.swinging 16k of them every chance I get. Anything can happen at any time.
-
Either way I’ll swing half my shares. Shitty management with no PR just means this will not runup much.
-
All Quay has to do is release the updates that was promised over a month ago. Only one reason to drag ass and that’s if the results aren’t good.
-
What do you expect, great potential products, shitty management.
-
Sold at 3.24 and rebought at 3.14 $1400 in two days just selling and buying the dip that happens every morning. Should have been doing this all along.
-
Headed to red. No trial results, nothing to prop it up.
-
Please stfu about Shorts being in trouble. Y’all look dumber every damn day with this bullshit. I’m bullish on this but some of y’all are straight up dumb when it comes to knowing the market and the process.
-
Wtf y’all keep worrying about Shorts? They gonna do what they gonna do.
-
Because they never reach potential lol. Quay prefers to chase conspiracy theories instead of releasing trial updates.
-
Please let this get bought out by someone with a competent PR dept.
-
Watch Quay get suicided and everything collapses
-
company just refuses to give results updates. At this point I’m starting to suspect they aren’t very positive.
-
Let’s hope he doesn’t get harsh pushback from members of Congress. Realize he is going against the narrative that many of them have clung to. Don’t be surprised if a few don’t try to spin it as “Asian hate”. Especially Democrats.
-
Daytraders dream stock here. Every day .15 cent swings. 10k shares nets you $1500 every single time. No Brainer to just keep taking the easy profits every day and hold some shares back in case of news dropping. Of course you’ll have to hear the “pApEr hANdS” cries from the fake Longs, but who gives a crap when you are actually pocketing money every day instead of waiting on this clown show of a management team to release something.
-
Lol dayum I knew I shoulda just kept daytrading this instead of playing those $7 options.
-
Finally took my brother-in-law advice and sold half of my shares at open and played the dip. 5000 shares at 3.25 and bought them back at 3.17. Quick $400. First money I’ve made in weeks since I put everything I had into this.
-
If he can work in the Covid Nasal Spray into the discussion it will be parabolic. Free press either way
-
That makes no sense. You apparently have no clue how shorting works. Why would they willingly sustain big losses like that, when they could simply cover now and then take up a Long position?
-
Atos: contract to reinforce a supercomputer in Sweden
news.google.com • -
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
globenewswire.com • -
3 Dirt-Cheap Drug Developers With Blockbuster Potential
investorplace.com • -
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025
investorplace.com • -
Atossa Therapeutics names Heather Rees as CFO
proactiveinvestors.com • -
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
globenewswire.com • -
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
globenewswire.com • -
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
investorplace.com • -
Atossa to Present at the Sidoti Small-Cap Investor Conference
globenewswire.com •